Home›Ombitasvir›Ombitasvir + Fosamprenavir Calcium

Does Ombitasvir Interact with Fosamprenavir Calcium?

CDI records a unknown classification for Ombitasvir and Fosamprenavir Calcium. The stored summary is: HCV protease inhibitor: Paritaprevir (coformulated with ritonavir and ombitasvir and coadministered with dasabuvir) Fosamprenavir calcium: ↑Amprenavir (predicted) ↑ or ↔Paritaprevir (predicted) Fosamprenavir calcium /ritonavir: ↑ or ↔Amprenavir (predicted) ↑Paritaprevir (predicted) Appropriate doses of the combinations with respect to safety and efficacy have not been established. Fosamprenavircalcium 1,400 mg once daily may be considered when coadministered with paritaprevir/ritonavir/ombitasvir/ dasabuvir. Coadministration of Fosamprenavircalcium /ritonavir and paritaprevir/ritonavir/ombitasvir/ dasabuvir is not recommended. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Severity: Unknown
Management: Consult your pharmacist
Data Source: U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Ombitasvir and your doctor is considering prescribing Fosamprenavir Calcium (or vice versa), make sure to:

Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
Ask whether the benefits of combining these medications outweigh the risks for your specific situation
Ask what symptoms to watch for that would indicate the interaction is causing problems
Never stop or change either medication without first consulting your healthcare provider

💊 Ombitasvir+💊 Fosamprenavir Calcium(Fosamprenavir Calcium)

Severity & Interaction Details

ℹ️

unknown

Interaction documented — severity unclassified

The CDI record includes an interaction but its severity has not been classified.

Severity scale

MinorContra

On record

Yes

Drug A class

—

Drug B class

—

Source

FDA drug label - fosamprenavir calcium

What this means in plain English

HCV protease inhibitor: Paritaprevir (coformulated with ritonavir and ombitasvir and coadministered with dasabuvir) Fosamprenavir calcium: ↑Amprenavir (predicted) ↑ or ↔Paritaprevir (predicted) Fosamprenavir calcium /ritonavir: ↑ or ↔Amprenavir (predicted) ↑Paritaprevir (predicted) Appropriate doses of the combinations with respect to safety and efficacy have not been established. Fosamprenavircalcium 1,400 mg once daily may be considered when coadministered with paritaprevir/ritonavir/ombitasvir/ dasabuvir. Coadministration of Fosamprenavircalcium /ritonavir and paritaprevir/ritonavir/ombitasvir/ dasabuvir is not recommended.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: FDA drug label - fosamprenavir calcium

Recent research & FDA safety updates

Live

Auto-aggregated from PubMed E-utilities and FDA safety data.

PubMed

Pharmacovigilance assessment of gout: a real-world study using the FAERS database.about Ombitasvir · 2026-07

PubMed

OATP1B3 c.699G>A Predicts a 6.3-Fold Increased Risk of Hyperbilirubinemia During OPrD Therapy for HCV.about Ombitasvir · 2026-04

PubMed

Repurposing antiviral drugs targeting RNA viruses: A focus on the fusion protein of human metapneumovirus.about Ombitasvir · 2026-04

Share this result:

WhatsApp Text / SMS Email

Also share on:X Facebook

Add more drugs

Check Ombitasvir and Fosamprenavir Calcium against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.